Table 1.
Biomarkers for blood-based liquid biopsy in gastrointestinal cancers
|
Cancer type
|
Biomarker type
|
Biomarkers
|
No. of patients /controls
|
Accuracy
|
Ref.
|
| GC | cfDNA copy number | HER2 gene | 60/30 | Sn = 73.3%, Sp = 93.3% | [19] |
| GC | cfDNA methylation | BARHL2 | 128/30 | Sn = 90%, Sp = 100% | [104] |
| GC | CTC | CTC level | 116/31 | Sn = 85.3%, Sp = 90.3% | [49] |
| GC | Exosomal lncRNA | lncRNA-UEGC1 | 10/5 | AUC = 0.876 | [105] |
| GC | Exosomal lncRNA | lncRNA-pcsk2-2:1 | 63/29 | Sn = 84%, Sp = 86.5% | [77] |
| GC | Exosomal lncRNA | lncRNA-GNAQ6:1 | 43/27 | AUC = 0.732 | [71] |
| GC | Exosomal lncRNA | lncRNA-HOTTIP | 126/120 | AUC = 0.827 | [106] |
| GC | Exosomal miRNA | miR-1246 | 117/82 | AUC = 0.843 | [107] |
| GC | Serum cfRNA | miR-10b-5p, miR-195-5p, miR-185-5p, miR-296-5p, miR-132-3p, and miR-20a-3p | 441/233 | AUC = 0.702 | [68] |
| GC | Serum cfRNA | miR-21 | 50/50 | Sn = 88.4%, Sp = 79.6% | [81] |
| GC | Serum cfRNA | miR-30a-5p, miR-659-3p and miR-3917 | 354 | AUC = 0.82 | [82] |
| GC | Serum cfRNA | B3GALT5-AS1 | 107/87 | AUC = 0.816 | [108] |
| CRC | CTC mRNA | ECT2 gene | 90/151 | AUC = 0.821 | [61] |
| CRC | Serum cfRNA | miR-21, miR-29a, miR-125b | 160/77 | AUC = 0.827 | [86] |
| CRC | Serum cfRNA | miR-30a-5p | 138/60 | Sn = 77.5%, Sp = 78.3% | [109] |
| CRC | cfDNA methylation | SFRP2 | 62/55 | Sn = 69.4%, Sp = 87.3% | [21] |
| CRC | CTC protein | CD133+CD54+CD44+ Protein | 10/10 | Sn = 88.2%, Sp = 92.4% | [62] |
| CRC | Exosomal miRNA | miR-27a, miR-130a | 40/40 | AUC = 0.773 | [110] |
| CRC | Exosomal miRNA | miR-125a-3p | 50/50 | AUC = 0.685 | [111] |
| CRC | Exosomal protein | CPNE3 | 92/32 | Sn = 67.5%, Sp = 84.4% | [112] |
| PC | CTC protein | Vimentin | 100/30 | AUC = 0.968 | [58] |
| PC | cfDNA methylation | BNC1, ADAMTS1 | 39/95 | Sn = 94.8%, Sp = 91.6% | [23] |
| PC | cfDNA methylation | CDO1 | 160 | Sn = 95% | [24] |
| PC | CTC | CTC level | 126 | Sn = 100%, Sp = 88.6% | [113] |
| PC | Exosomal lncRNA | CLDN1, TIMP1, MAL2, MARCH2, ITIH2, HIST1H2BK, KRT19 and FGA | 284/117 | AUC = 0.931 | [79] |
| PC | Exosomal miRNA | miR-21 | 27 | AUC = 0.9 | [76] |
| PC | Exosomal miRNA | miR-155 | 27 | AUC = 0.89 | [76] |
| PC | Exosomal miRNA | miR-451a | 56 | Sn = 69.2%, Sp = 70.8% | [114] |
| PC | Exosomal miRNA | miR-133a | 110/64 | Sn = 90.6%, Sp = 87.2%, AUC = 0.893 | [115] |
| HCC | cfDNA methylation | cfDNA 5hmC | 1204/958 | AUC = 0.846 | [30] |
| HCC | Exosomal miRNA | miR-10b-5p | 90/28 | AUC = 0.934 | [75] |
| HCC | Exosomal mRNA | hnRNPH1 | 88/68 | Sn = 85.2%, Sp = 76.5% | [80] |
| HCC | Plasma cfRNA | hsa_circ_0000976, hsa_circ_0007750 and hsa_circ_0139897 | 158/53 | AUC = 0.863 | [85] |
| HCC | Serum cfRNA | miR-143 | 131/122 | Sn = 80.3%, Sp = 82.4% | [87] |
| HCC | Serum cfRNA | miR-132, miR-212` | 80/42 | Sn = 93.75%, Sp = 63.44% | [116] |
GC: Gastric cancer; CRC: Colorectal cancer; PC: Pancreatic cancer; HCC: Hepatocellular carcinoma; Sn: Sensitivity; Sp: Specificity; AUC: Area under the curve.